British multinational pharmaceutical and biotech company GSK announced a three-year agreement with a $70 million initial payment to expand its access to Tempus' AI-powered data library, including its de-identified patient data.
GSK says the collaboration will allow it to leverage the U.S.-based company's library to accelerate drug discovery in oncology, improve its clinical trial design,...
23andMe reported a $217 million net loss during its fiscal year 2022, which ended March 31, compared with $184 million during the prior year.
The consumer genetics company also posted a loss of $70 million during its fourth quarter, compared with $67 million during Q4 2021. 23andMe attributed the increase in net loss during the quarter to increased operating expenses driven by sales and...
Qure.ai scored FDA 510(k) clearance for its artificial intelligence algorithm that assists providers in placing breathing tubes.
The clearance, which officially came down in late December, is the company's third 510(k). The two previous FDA green lights were regarding its brain CT scan product.
Using chest x-rays, the qXR-BT algorithm can analyze the position of the breathing tube. It automates...
Consumer genetics company 23andMe scored FDA 510(k) clearance for a test to detect a hereditary marker for prostate cancer.
The risk report provides information on whether users have the G84E mutation in the HOXB13 gene, which studies have shown can increase a person’s risk of developing prostate cancer.
This FDA greenlight marks 23andMe’s third 510(k). It also has four De Novo clearances, one of...
Though COVID-19 vaccines began their rollout to the public, 2021 was still a turbulent year for healthcare providers as they weathered new virus variants, staffing shortages and burnout.
But the pandemic also created a new wave of interest in virtual care and telehealth. Many providers turned toward the modality to keep in contact with patients in 2020, but startups and other organizations are...
Just after closing a $100 million funding round, H1 named Ziad Ismail as its new chief operating officer. He comes to H1 from Convoy, where he also served as the chief product officer. He previously held roles at Marchex, CitiKey and Microsoft.
“H1 has amassed an enormous amount of quality healthcare data that life science companies, hospitals and academic medical centers simply cannot find...
Consumer genetics company 23andMe announced Friday it has signed a definitive agreement to acquire telehealth and online prescription platform Lemonaid Health for $400 million.
The price tag, subject to downward adjustments, will be made up of 25% in cash and 75% in stock. The companies expect the acquisition to close by the end of the year.
“We believe that by combining Lemonaid Health’s...
Doximity, a social networking platform for healthcare providers, has shared the terms for its upcoming initial public offering of 23,300,000 shares of its Class A common stock.
The offering consists of about 19 million shares offered by Doximity and 4.3 million shares to be sold by an existing stockholder, of which the company will not profit. An additional 3.5 million shares from Doximity will...
Consumer genomics platform 23andMe is on its way to becoming a publicly-traded company through its merger with VG Acquisition Corp., a special purpose acquisition company sponsored by Virgin Group.
The two companies announced today they have entered into a definitive merger agreement that is expected to close in the second quarter of this year. Once completed, the combined companies’ stock will...
23andMe's new COVID-19 resource. Consumer genomics company 23andMe has released a new interactive tool that allows users to see how various health factors could impact the risk of COVID-19 hospitalization. The COVID-19 Severity Calculator pulls data from the company's COVID-19 study, which included 10,000 participants diagnosed with the disease and 750 who were hospitalized.
23andMe warned that...
